DK2177528T3 - Fremgangsmåde til fremstilling af blandinger af trifluoracetylglatirameracetat ved anvendelse af oprenset hydrogenbromid - Google Patents

Fremgangsmåde til fremstilling af blandinger af trifluoracetylglatirameracetat ved anvendelse af oprenset hydrogenbromid

Info

Publication number
DK2177528T3
DK2177528T3 DK10150124.5T DK10150124T DK2177528T3 DK 2177528 T3 DK2177528 T3 DK 2177528T3 DK 10150124 T DK10150124 T DK 10150124T DK 2177528 T3 DK2177528 T3 DK 2177528T3
Authority
DK
Denmark
Prior art keywords
hydrogen bromide
glatiramer acetate
purified hydrogen
preparing mixtures
trifluoroacetyl glatiramer
Prior art date
Application number
DK10150124.5T
Other languages
Danish (da)
English (en)
Inventor
Ben-Zion Dolitzky
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36037047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2177528(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of DK2177528T3 publication Critical patent/DK2177528T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK10150124.5T 2004-09-09 2005-09-09 Fremgangsmåde til fremstilling af blandinger af trifluoracetylglatirameracetat ved anvendelse af oprenset hydrogenbromid DK2177528T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60884304P 2004-09-09 2004-09-09
EP05791236A EP1799703B1 (en) 2004-09-09 2005-09-09 Process for preparation of mixtures of polypeptides using purified hydrobromic acid

Publications (1)

Publication Number Publication Date
DK2177528T3 true DK2177528T3 (da) 2012-03-26

Family

ID=36037047

Family Applications (3)

Application Number Title Priority Date Filing Date
DK05791236.2T DK1799703T3 (da) 2004-09-09 2005-09-09 Fremgangsmåde til fremstilling af blandinger af polypeptider ved hjælp af oprenset hydrogenbromid
DK10150124.5T DK2177528T3 (da) 2004-09-09 2005-09-09 Fremgangsmåde til fremstilling af blandinger af trifluoracetylglatirameracetat ved anvendelse af oprenset hydrogenbromid
DK10194363.7T DK2361924T3 (en) 2004-09-09 2005-09-09 A process for the preparation of mixtures of trifluoroacetyl glatiramer acetate using purified hydrobromic acid

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK05791236.2T DK1799703T3 (da) 2004-09-09 2005-09-09 Fremgangsmåde til fremstilling af blandinger af polypeptider ved hjælp af oprenset hydrogenbromid

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10194363.7T DK2361924T3 (en) 2004-09-09 2005-09-09 A process for the preparation of mixtures of trifluoroacetyl glatiramer acetate using purified hydrobromic acid

Country Status (27)

Country Link
US (2) US7495072B2 (OSRAM)
EP (3) EP1799703B1 (OSRAM)
JP (1) JP5149008B2 (OSRAM)
KR (1) KR101317131B1 (OSRAM)
CN (1) CN101166754B (OSRAM)
AT (2) ATE536363T1 (OSRAM)
AU (1) AU2005282249B2 (OSRAM)
BR (1) BRPI0515033B1 (OSRAM)
CA (1) CA2579656C (OSRAM)
CY (1) CY1110280T1 (OSRAM)
DE (1) DE602005018800D1 (OSRAM)
DK (3) DK1799703T3 (OSRAM)
ES (3) ES2451006T3 (OSRAM)
HR (3) HRP20100164T1 (OSRAM)
IL (2) IL181596A (OSRAM)
IS (1) IS8622A (OSRAM)
MX (1) MX2007002760A (OSRAM)
NO (1) NO20071632L (OSRAM)
NZ (1) NZ554018A (OSRAM)
PL (3) PL2361924T3 (OSRAM)
PT (3) PT1799703E (OSRAM)
RS (3) RS53248B (OSRAM)
RU (1) RU2388764C2 (OSRAM)
SI (3) SI2361924T1 (OSRAM)
UA (1) UA91029C2 (OSRAM)
WO (1) WO2006029393A2 (OSRAM)
ZA (1) ZA200702591B (OSRAM)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
CA2337688C (en) 1998-07-23 2016-04-05 Yeda Research And Development Co., Ltd. Treatment of autoimmune conditions with copolymer 1 and related copolymers
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
DE60237170D1 (de) * 2001-12-04 2010-09-09 Teva Pharma Verfahren zur messung der wirkstärke von glatirameracetat
EP1778286A4 (en) * 2004-03-03 2009-04-08 Teva Pharma COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
MX2007002760A (es) * 2004-09-09 2007-05-18 Teva Pharma Procedimiento para la preparacion de mezclas de polipeptidos y utilizando acido bromhidrico purificado.
WO2006029411A2 (en) * 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
US8324641B2 (en) * 2007-06-29 2012-12-04 Ledengin, Inc. Matrix material including an embedded dispersion of beads for a light-emitting device
ES2331015T3 (es) * 2004-10-29 2009-12-18 Sandoz Ag Proceso para la preparacion de un glatiramero.
NZ556156A (en) * 2005-02-02 2010-03-26 Teva Pharma Process for producing acetate salts of polypeptides using hydrogenolysis
PT1848415E (pt) * 2005-02-17 2013-06-27 Teva Pharma Terapia de combinação com acetato de glatirâmero e rasagilina para o tratamento da esclerose múltipla
EP1891233A4 (en) * 2005-04-25 2010-03-24 Yeda Res & Dev MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE
WO2009017775A2 (en) * 2007-08-02 2009-02-05 Scinopharm Taiwan Ltd. Process for the preparation of a polypeptide
AU2008330093A1 (en) * 2007-11-28 2009-06-04 Yeda Research And Development Co., Ltd. Method of delaying the onset of clinically definite multiple sclerosis
EP2277050B2 (en) 2008-04-16 2022-09-28 Momenta Pharmaceuticals, Inc. Analysis of amino acid copolymer compositions
KR20110059606A (ko) * 2008-08-07 2011-06-02 시노팜 타이완 리미티드 글라티라머 아세테이트의 합성
WO2010017075A1 (en) * 2008-08-07 2010-02-11 Sigma-Aldrich Co. Preparation of low molecular weight polylysine and polyornithine in high yield
US8859489B2 (en) * 2009-04-03 2014-10-14 Momenta Pharmaceuticals, Inc. Water-mediated control of depolymerization step of glatiramer acetate synthesis
UA103699C2 (ru) 2009-08-20 2013-11-11 Еда Рисёрч Энд Девелопмент Ко., Лтд. Терапия глатирамера ацетатом с низкой частотой
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
EP2563804A4 (en) * 2010-04-27 2014-09-17 Reddys Lab Ltd Dr PREPARATION OF POLYPEPTIDES AND THEIR SALTS
EA025780B1 (ru) 2010-10-11 2017-01-30 Тева Фармасьютикал Индастриз Лтд. Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
US8788046B2 (en) 2010-11-11 2014-07-22 Spr Therapeutics, Llc Systems and methods for the treatment of pain through neural fiber stimulation
CA2827275A1 (en) * 2011-02-14 2012-09-20 Usv Limited Copolymer-1, process for preparation and analytical methods thereof
JP5701103B2 (ja) * 2011-03-02 2015-04-15 昭和シェル石油株式会社 潤滑油のための消泡剤組成物及びそれを用いた消泡方法
WO2012143924A1 (en) 2011-04-21 2012-10-26 Mapi Pharma Ltd. Random pentapolymer for treatment of autoimmune diseases
WO2013009864A1 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Structure assessment of heterogeneous polypeptide mixtures
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
CA2851510A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
CN102717992A (zh) * 2012-05-30 2012-10-10 苏州市旭洋工业搪瓷厂 一种搪玻璃溴素贮罐
CN102718963B (zh) * 2012-06-19 2014-10-15 深圳翰宇药业股份有限公司 聚合物多肽的制备方法
TW201420111A (zh) 2012-10-10 2014-06-01 Teva Pharma 對格拉默醋酸鹽(glatiramer acetate)之臨床反應具預測性之生物標記
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
WO2015066515A1 (en) 2013-11-01 2015-05-07 Receptos, Inc. Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
CN104844697B (zh) 2014-09-26 2018-10-23 深圳翰宇药业股份有限公司 醋酸格拉替雷的制备方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
US12370233B2 (en) 2016-08-31 2025-07-29 Mapi Pharma Ltd. Depot systems comprising glatiramer acetate
WO2018178973A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
US20190202984A1 (en) * 2018-01-03 2019-07-04 Kinbio Ltd. Process of preparing glatiramer acetate

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3846550A (en) * 1971-01-21 1974-11-05 H Akrongold Cosmetic skin powder containing urea
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
JPS54119499A (en) * 1978-03-09 1979-09-17 Shionogi & Co Ltd Triazolobenzodiazepin derivative
JPS6053535A (ja) * 1983-09-02 1985-03-27 Nitto Boseki Co Ltd 規則性ポリアミノ酸樹脂の製造方法
SU1182051A1 (ru) 1984-04-28 1985-09-30 Таджикский государственный университет им.В.И.Ленина Политрипептиды,обладающие энантовой селективностью в реакци х гидролиза @ -нитрофениловых эфиров карбобензокси - @ - и @ -аланина
AU596986B2 (en) 1985-06-18 1990-05-24 Emory University Biologically-active copolymers
DD257174A3 (de) 1985-12-20 1988-06-08 Ve Forschungszentrum Biotechno Verfahren zur herstellung der peptide z-ala-ala-lon-p-nitranilid oder z-asp-phe-ome mit metalloprotease
SU1469826A1 (ru) 1986-05-30 1995-11-20 Институт Высокомолекулярных Соединений Ан Ссср Сополимер l-лизина с l-глутаминовой кислотой, содержащий дофаминовые боковые группы, обладающий пролонгированной гипотензивной активностью и компенсаторным эффектом при геморрагическом шоке, и способ его получения
SU1690368A1 (ru) 1989-07-20 1995-08-20 Институт Высокомолекулярных Соединений Ан Ссср Статистические сополимеры в качестве низкотоксичных веществ, обладающих пролонгированным гипотензивным действием, и способ их получения
DE3930733A1 (de) 1989-09-14 1991-03-28 Roehm Gmbh Verfahren zur herstellung eines komplexierten arzneimittels
USH1312H (en) * 1992-05-28 1994-05-03 Cytogen Corporation Method for the preparation of gyk-dtpa
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
RU2161489C2 (ru) * 1994-05-24 2001-01-10 Еда Рисерч энд Дивелопмент Ко. Лтд. Усовершенствованный сополимер-1 в сополимерных композициях
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
FR2750423B1 (fr) 1996-06-28 1998-08-14 Rhone Poulenc Chimie Procede d'hydrogenation asymetrique d'un compose cetonique
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
KR20010015639A (ko) 1997-09-30 2001-02-26 스즈키 다다시 술포닐 유도체
US5872122A (en) * 1997-10-16 1999-02-16 Monsanto Company Pyrimidinylamidino β-amino acid derivatives useful as inhibitors of platelet aggregation
US5965047A (en) 1997-10-24 1999-10-12 Steag Ast Rapid thermal processing (RTP) system with rotating substrate
GB9724627D0 (en) 1997-11-20 1998-01-21 Genencor Int Bv Gram positive microorganism formate pathway
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
CA2337688C (en) 1998-07-23 2016-04-05 Yeda Research And Development Co., Ltd. Treatment of autoimmune conditions with copolymer 1 and related copolymers
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
EP1128839A4 (en) 1998-11-12 2002-10-09 Yeda Res & Dev PHARMACEUTICAL COMPOSITIONS CONTAINING COPOLYMERS OF SYNTHETIC PEPTIDES AND METHODS FOR PREVENTING AND TREATING GVHD AND HVGD
US6114649A (en) 1999-07-13 2000-09-05 Duran Technologies Inc. Anode electrode for plasmatron structure
EP1250450A2 (en) 1999-09-03 2002-10-23 University of Iowa Research Foundation Inc. Quorum sensing signaling in bacteria
DE19944003C1 (de) 1999-09-14 2001-03-22 Baumeister & Ostler Gmbh Co Faltbare Trenneinrichtung
PT1248643E (pt) 2000-01-20 2005-10-31 Yeda Res & Dev Utilizacao de copolimero 1 e peptidos e polipeptidos congeneres e de celulas t tratadas co estes compostos para terapia neuroprotectora
MXPA02008023A (es) 2000-02-18 2005-06-30 Yeda Res & Dev Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar.
ZA200206457B (en) * 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
EP1294390B1 (en) 2000-06-07 2006-01-04 YEDA RESEARCH AND DEVELOPMENT CO., Ltd. The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotection from glutamate toxicity
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
JP3698984B2 (ja) 2000-11-10 2005-09-21 ヤマウチ株式会社 シュープレス用ベルト
EP1351686A2 (en) * 2000-11-20 2003-10-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
JP3661935B2 (ja) 2001-06-20 2005-06-22 ソニー株式会社 情報処理装置および方法、記録媒体、並びにプログラム
DE60237170D1 (de) * 2001-12-04 2010-09-09 Teva Pharma Verfahren zur messung der wirkstärke von glatirameracetat
WO2004036172A2 (en) 2002-05-09 2004-04-29 Dennis Farwell Bioweapon-detecting fibrous-network products and methods for making same
CA2411786C (en) * 2002-11-13 2009-01-27 Brantford Chemicals Inc. A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids
AU2003283152A1 (en) * 2002-11-13 2004-06-03 Apotex Pharmachem Inc. Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
DE10353960B4 (de) 2003-10-16 2006-03-23 Vertilas Gmbh Oberflächenemittierender Halbleiterlaser mit strukturiertem Wellenleiter
WO2006029411A2 (en) * 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
MX2007002760A (es) * 2004-09-09 2007-05-18 Teva Pharma Procedimiento para la preparacion de mezclas de polipeptidos y utilizando acido bromhidrico purificado.
NZ556156A (en) * 2005-02-02 2010-03-26 Teva Pharma Process for producing acetate salts of polypeptides using hydrogenolysis
EP1891233A4 (en) * 2005-04-25 2010-03-24 Yeda Res & Dev MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE
WO2007072865A1 (ja) 2005-12-22 2007-06-28 Pioneer Corporation 施設情報配信装置、通信端末、施設情報配信方法、情報出力方法、プログラム、および記録媒体

Also Published As

Publication number Publication date
SI2361924T1 (sl) 2014-04-30
MX2007002760A (es) 2007-05-18
BRPI0515033A8 (pt) 2019-01-22
RS53248B (sr) 2014-08-29
ES2451006T3 (es) 2014-03-26
ES2338138T3 (es) 2010-05-04
PT2177528E (pt) 2012-03-19
HRP20100164T1 (hr) 2010-07-31
EP2361924B1 (en) 2013-12-11
IL181596A0 (en) 2007-07-04
DK2361924T3 (en) 2014-03-10
HRP20120209T1 (hr) 2012-06-30
SI2177528T1 (sl) 2012-04-30
RU2388764C2 (ru) 2010-05-10
JP2008512494A (ja) 2008-04-24
JP5149008B2 (ja) 2013-02-20
EP2361924A1 (en) 2011-08-31
UA91029C2 (uk) 2010-06-25
DE602005018800D1 (de) 2010-02-25
KR101317131B1 (ko) 2013-10-10
RS51257B (sr) 2010-12-31
IL181596A (en) 2015-10-29
NO20071632L (no) 2007-06-05
BRPI0515033B1 (pt) 2021-05-25
IL241702A0 (en) 2015-11-30
SI1799703T1 (sl) 2010-04-30
WO2006029393A2 (en) 2006-03-16
EP1799703A2 (en) 2007-06-27
EP1799703B1 (en) 2010-01-06
CY1110280T1 (el) 2015-01-14
PT1799703E (pt) 2010-03-04
WO2006029393A3 (en) 2007-12-13
AU2005282249B2 (en) 2012-08-02
ZA200702591B (en) 2009-03-25
BRPI0515033A (pt) 2008-07-01
HRP20140216T1 (hr) 2014-06-06
US20060052586A1 (en) 2006-03-09
US7495072B2 (en) 2009-02-24
NZ554018A (en) 2009-06-26
EP2177528A1 (en) 2010-04-21
EP2177528B1 (en) 2011-12-07
PT2361924E (pt) 2014-03-13
ATE454396T1 (de) 2010-01-15
ES2382298T3 (es) 2012-06-07
KR20070059137A (ko) 2007-06-11
WO2006029393A8 (en) 2007-04-19
AU2005282249A1 (en) 2006-03-16
CN101166754B (zh) 2014-04-23
RS52265B (sr) 2012-10-31
HK1140775A1 (en) 2010-10-22
ATE536363T1 (de) 2011-12-15
DK1799703T3 (da) 2010-04-19
RU2007112956A (ru) 2008-10-20
HK1156637A1 (en) 2012-06-15
CN101166754A (zh) 2008-04-23
CA2579656C (en) 2014-11-04
PL1799703T3 (pl) 2010-06-30
PL2177528T3 (pl) 2012-09-28
IS8622A (is) 2007-03-16
EP1799703A4 (en) 2008-09-03
PL2361924T3 (pl) 2014-08-29
US20070021324A1 (en) 2007-01-25
CA2579656A1 (en) 2006-03-16
HK1100780A1 (en) 2007-09-28

Similar Documents

Publication Publication Date Title
DK2177528T3 (da) Fremgangsmåde til fremstilling af blandinger af trifluoracetylglatirameracetat ved anvendelse af oprenset hydrogenbromid
UA93669C2 (ru) Способ приготовления полипептидной смеси c использованием гидрогенолиза
DK1961811T3 (da) Cytokinligand til behandling af asthma og luftvejs-hyper-responsivitet
DK1144607T5 (da) Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger
IN2014CN02050A (OSRAM)
FI20050243A7 (fi) Stabiilia bakterisidista/läpäisevyyttä parantavaa proteiinifragmenttia koodittava DNA, vektori, isäntäsolu ja menetelmä näiden proteiinipigmenttien valmistamiseksi
EP1801206A4 (en) PROCESS FOR THE PREPARATION OF L-ARGININE, L-ORNITHIN OR L-CITRULLINE
DE69723812D1 (de) Aminosäurezusammensetzungen
DE602004028266D1 (de) Angiogene peptide und ihre verwendungen
WO2003075944A3 (en) Interferon beta-like molecules for treatment of stroke
WO2005042717A3 (en) Primate prokineticin and prokineticin receptor polypeptides, related compositions and methods
DE60104702D1 (de) Auftrennung von isomeren von n-[n-(3,3-dimethylbutyl)-l- alpha-aspartyl]-l-phenylalanin-1-methylester durch verwendung mittels metallischer ionen
CY1115096T1 (el) Διαδικασια για την παρασκευη μιγματων trifluoroacetyl glatiramer acetate χρησιμοποιωντας καθαρισμενο υδροβρωμικο οξυ
EP1559721A4 (en) NEW FPRL1 LIGANDS AND THEIR USE
EP1467207A4 (en) Screening method
ATE321847T1 (de) Hydantoinracemase
DK1551863T3 (da) Fremgangsmåde til syntese af peptider, der omfatter mindst ét glycinmolekyle
WO2003102209A3 (en) Alternatively spliced isoforms of human hmg co-a reductase
WO2007026171A3 (en) Vdcc gamma-8 ion channel